TWI870286B - 五環化合物之鹽及其等之結晶 - Google Patents
五環化合物之鹽及其等之結晶 Download PDFInfo
- Publication number
- TWI870286B TWI870286B TW113114065A TW113114065A TWI870286B TW I870286 B TWI870286 B TW I870286B TW 113114065 A TW113114065 A TW 113114065A TW 113114065 A TW113114065 A TW 113114065A TW I870286 B TWI870286 B TW I870286B
- Authority
- TW
- Taiwan
- Prior art keywords
- thieno
- crystals
- compound
- diffraction
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019039349 | 2019-03-05 | ||
| JP2019-039349 | 2019-03-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202430531A TW202430531A (zh) | 2024-08-01 |
| TWI870286B true TWI870286B (zh) | 2025-01-11 |
Family
ID=72337486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113114065A TWI870286B (zh) | 2019-03-05 | 2020-03-03 | 五環化合物之鹽及其等之結晶 |
| TW109106928A TWI849070B (zh) | 2019-03-05 | 2020-03-03 | 五環化合物之鹽及其等之結晶 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109106928A TWI849070B (zh) | 2019-03-05 | 2020-03-03 | 五環化合物之鹽及其等之結晶 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11420980B2 (https=) |
| EP (1) | EP3936189A4 (https=) |
| JP (1) | JP7508441B2 (https=) |
| KR (1) | KR102921161B1 (https=) |
| CN (1) | CN113646046B (https=) |
| AU (1) | AU2020233452B2 (https=) |
| BR (1) | BR112021015979A2 (https=) |
| CA (1) | CA3129764A1 (https=) |
| MX (1) | MX2021009774A (https=) |
| TW (2) | TWI870286B (https=) |
| WO (1) | WO2020179781A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020179780A1 (ja) | 2019-03-05 | 2020-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式複素環化合物 |
| PT119624A (pt) * | 2024-07-29 | 2026-01-29 | Silva Escada Guilherme | Máquina modular para a dobragem de tubos de pvc |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187306A (en) * | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
| US5859016A (en) * | 1995-06-20 | 1999-01-12 | Je Il Pharmaceutical Co., Ltd. | Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient |
| TW201920195A (zh) * | 2017-09-07 | 2019-06-01 | 日商衛材R&D企管股份有限公司 | 五環化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD258234A1 (de) | 1987-03-05 | 1988-07-13 | Univ Leipzig | Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine |
| RU2117670C1 (ru) | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
| TW197442B (https=) * | 1990-02-08 | 1993-01-01 | Pfizer | |
| US5621100A (en) * | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5756494A (en) * | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| CL2004000348A1 (es) | 1997-04-15 | 2005-01-14 | Cephalon Inc & Kyowa Hakko Kog | Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales. |
| CL2004000352A1 (es) | 1998-05-26 | 2005-05-27 | Cephalon Inc & Kyowa Hakko Kog | Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales. |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US8252520B2 (en) | 2002-10-11 | 2012-08-28 | Taivex Therapeutics Corporation | Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases |
| AU2005299031B2 (en) | 2004-10-20 | 2011-11-10 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| US9314318B2 (en) * | 2008-08-26 | 2016-04-19 | Zest Ip Holdings, Llc | Dental anchor apparatus and method |
| WO2020179780A1 (ja) | 2019-03-05 | 2020-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式複素環化合物 |
-
2020
- 2020-03-03 WO PCT/JP2020/008889 patent/WO2020179781A1/ja not_active Ceased
- 2020-03-03 EP EP20766851.8A patent/EP3936189A4/en active Pending
- 2020-03-03 TW TW113114065A patent/TWI870286B/zh active
- 2020-03-03 KR KR1020217025603A patent/KR102921161B1/ko active Active
- 2020-03-03 TW TW109106928A patent/TWI849070B/zh active
- 2020-03-03 BR BR112021015979-7A patent/BR112021015979A2/pt unknown
- 2020-03-03 AU AU2020233452A patent/AU2020233452B2/en active Active
- 2020-03-03 MX MX2021009774A patent/MX2021009774A/es unknown
- 2020-03-03 JP JP2021504108A patent/JP7508441B2/ja active Active
- 2020-03-03 CA CA3129764A patent/CA3129764A1/en active Pending
- 2020-03-03 CN CN202080014060.2A patent/CN113646046B/zh active Active
- 2020-09-15 US US17/021,544 patent/US11420980B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187306A (en) * | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
| US5859016A (en) * | 1995-06-20 | 1999-01-12 | Je Il Pharmaceutical Co., Ltd. | Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient |
| TW201920195A (zh) * | 2017-09-07 | 2019-06-01 | 日商衛材R&D企管股份有限公司 | 五環化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3936189A1 (en) | 2022-01-12 |
| JP7508441B2 (ja) | 2024-07-01 |
| BR112021015979A2 (pt) | 2021-10-05 |
| KR20210135223A (ko) | 2021-11-12 |
| US11420980B2 (en) | 2022-08-23 |
| CN113646046A (zh) | 2021-11-12 |
| KR102921161B1 (ko) | 2026-02-02 |
| TWI849070B (zh) | 2024-07-21 |
| MX2021009774A (es) | 2021-09-08 |
| JPWO2020179781A1 (https=) | 2020-09-10 |
| CN113646046B (zh) | 2024-05-17 |
| AU2020233452A1 (en) | 2021-09-02 |
| EP3936189A4 (en) | 2022-12-14 |
| TW202430531A (zh) | 2024-08-01 |
| WO2020179781A1 (ja) | 2020-09-10 |
| AU2020233452B2 (en) | 2025-04-10 |
| TW202100531A (zh) | 2021-01-01 |
| US20210024541A1 (en) | 2021-01-28 |
| CA3129764A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503300A (ja) | 二環式oga阻害剤化合物 | |
| RU2754557C1 (ru) | Пентациклическое соединение | |
| JP7794910B2 (ja) | Eaat2活性化因子およびその使用方法 | |
| TWI870286B (zh) | 五環化合物之鹽及其等之結晶 | |
| EP4052706A1 (en) | Composition for preventing or inhibiting axonal degeneration | |
| JP6553081B2 (ja) | アダプター関連キナーゼ1の阻害剤、それを含む組成物、及びその使用方法 | |
| TW200904436A (en) | Arylamide pyrimidone derivatives | |
| RU2820938C2 (ru) | Соль пентациклического соединения и его кристалл | |
| US7465738B2 (en) | Compounds useful as promoters of SMN2 | |
| JP2001002572A (ja) | ニューロトロフィン作用増強剤 | |
| WO2026035920A1 (en) | (2-oxo-2h-chromen-3-yl) scaffold based carboxamide analogs as potent inhibitors of tau protein fibrils | |
| BR112020003197B1 (pt) | Composto pentacíclico |